Blueprint Medicines Corp

Blueprint Medicines — Jefferies Healthcare Conference 2022

24 slides from Blueprint Medicines's conference presentation, Jun 9, 2022

  1. Slide 1: Jefferies Healthcare Conference June 9, 2022

    Slide 1: Jefferies Healthcare Conference June 9, 2022

    JEFFERIES HEALTHCARE CONFERENCE JUNE 9, 2022 Kristine G. Systemic mastocytosis patient Pioneering the Science of Time Not for promotional use.

  2. Slide 2: Forward-looking statements

    Slide 2: Forward-looking statements

    Forward-looking statements 2 Not for promotional use. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, timelines and expectations for interactions w

  3. Slide 3: Blueprint Medicines is a global leader in precision therapy

    Slide 3: Blueprint Medicines is a global leader in precision therapy

    Blueprint Medicines is a global leader in precision therapy AYVAKIT is approved for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations, and adult patients with advanced SM, including aggressive SM, SM with an associated

  4. Slide 4: Blueprint is uniquely positioned with a diversity of significant growth drivers

    Slide 4: Blueprint is uniquely positioned with a diversity of significant growth drivers

    Blueprint is uniquely positioned with a diversity of significant growth drivers Ongoing global collaboration with Roche and Genentech for the development and commercialization of GAVRETO. FDA, U.S. Food and Drug Administration; EC, European Commission; PDGFRA, platelet-derived growth factor receptor

  5. Slide 5: Global Commercial Execution

    Slide 5: Global Commercial Execution

    Global Commercial Execution Cyndi N. Systemic mastocytosis patient Not for promotional use.

  6. Slide 6: We are establishing the standard of care for advanced SM

    Slide 6: We are establishing the standard of care for advanced SM

    We are establishing the standard of care for advanced SM 6 Not for promotional use. 1. Reported data represent estimations. Analysis based on US claims data AYVAKIT COMMERCIAL GROWTH NEW PATIENT STARTS DURATION OF THERAPY ~65 new accounts activated in Q1 2022 ~70% share of new AdvSM patient starts ~

  7. Slide 7: Retrospective analysis showed a longer OS among AYVAKIT patients

    Slide 7: Retrospective analysis showed a longer OS among AYVAKIT patients

    Retrospective analysis showed a longer OS among AYVAKIT patients A multi-center, global, observational, retrospective chart review study was conducted at 6 study sites (4 European, 2 US) to identify and collect data from AdvSM patients who received BAT. SM-AHN patients were identified using inclusio

  8. Slide 8: Clinical Stage Growth

    Slide 8: Clinical Stage Growth

    Clinical Stage Growth Rob T. Advanced cancer patient Not for promotional use.

  9. Slide 9: Non-advanced SM patients have high medical need despite available therapies

    Slide 9: Non-advanced SM patients have high medical need despite available therapies

    Non-advanced SM patients have high medical need despite available therapies1 95% of SM cases driven by the KIT D816V mutation SYSTEMIC MASTOCYTOSIS SYMPTOMS2 Brain fog Pruritis, flushing and pigmented skin lesions Life-threatening organ infiltration and damage Unpredictable, life-threatening anaphyl

  10. Slide 10: PIONEER Part 2 primary endpoint to be updated to mean change in TSS

    Slide 10: PIONEER Part 2 primary endpoint to be updated to mean change in TSS

    PIONEER Part 2 primary endpoint to be updated to mean change in TSS 1. PIONEER Part 1. Based upon a data cutoff of March 12, 2020. TSS, total symptom score; FDA, Food and Drug Administration; ISM-SAF, Indolent Systemic Mastocytosis Symptom Assessment Form; SAP, statistical analysis plan; EMA, Europe

  11. Slide 11: PIONEER Part 1 showed statistically significant difference in mean change in TSS

    Slide 11: PIONEER Part 1 showed statistically significant difference in mean change in TSS

    PIONEER Part 1 showed statistically significant difference in mean change in TSS between avapritinib and placebo 1. Hartmann K. et al. Avapritinib reduces cutaneous symptoms and mast cell burden in patients with indolent systemic mastocytosis in the PIONEER study. Presented at the European Academy o

  12. Slide 12: Key secondary endpoints are important to fully characterize the impact of avapritinib

    Slide 12: Key secondary endpoints are important to fully characterize the impact of avapritinib

    Key secondary endpoints are important to fully characterize the impact of avapritinib on patients with non-advanced SM 12 Not for promotional use. 1. Hartmann K. et al. Avapritinib reduces cutaneous symptoms and mast cell burden in patients with indolent systemic mastocytosis in the PIONEER study. P

  13. Slide 13: PIONEER Part 2 topline on track for late summer 2022

    Slide 13: PIONEER Part 2 topline on track for late summer 2022

    PIONEER Part 2 topline on track for late summer 2022 TSS, total symptom score; QD, once daily; BSC, best supportive care; ISM, indolent systemic mastocytosis; QoL, quality of life; MC-QoL, Mastocytosis Quality of Life Questionnaire; PGIS, Patient's Global Impression of Symptom Severity; PGIS, Patien

  14. Slide 14: Our portfolio of EGFR therapies is purpose-built to address medical needs

    Slide 14: Our portfolio of EGFR therapies is purpose-built to address medical needs

    Our portfolio of EGFR therapies is purpose-built to address medical needs CS, C797S resistance mutation; Ex20in, activating exon 20 insertion mutations; LR, L858R activating mutation; TM, T790M resistance mutation. 14 Not for promotional use. Effectively block the EGFR pathway Establish 2L+ SOC with

  15. Slide 15: BLU-945 potency and selectivity enable wide therapeutic index and broad EGFR coverage

    Slide 15: BLU-945 potency and selectivity enable wide therapeutic index and broad EGFR coverage

    BLU-945 potency and selectivity enable wide therapeutic index and broad EGFR coverage, with promising early clinical monotherapy data 15 aOne patient had two different DNA mutations in C797S. Note: reductions in individual variant allele fractions as shown; therefore, patients with multiple mutation

  16. Slide 16: Phase 1/2 trials to rapidly generate data in broad populations

    Slide 16: Phase 1/2 trials to rapidly generate data in broad populations

    Phase 1/2 trials to rapidly generate data in broad populations, informing development and registration strategies PLANNED INITIATION OF PHASE 1/2 SYMPHONY / HARMONY TRIAL COHORTS 1L 2L+ 2023 701 + ADC All comer 945 + osi LR 701 + chemo All comer 701 + osi All comer Q2 2022 945 + osi LR + CS +/- TM 9

  17. Slide 17: Opportunity to influence the treatment paradigm for more than 100K patients across CDK2-vulnerable cancers

    Slide 17: Opportunity to influence the treatment paradigm for more than 100K patients across CDK2-vulnerable cancers

    Opportunity to influence the treatment paradigm for more than 100K patients across multiple CDK2-vulnerable cancers1 17 CDK-CYCLIN COMPLEXES REGULATE THE CELL CYCLE ABERRANT CYCLIN E (CCNE1) DRIVES CELL PROLIFERATION CDK4/6 Cyclin D CDK2 Cyclin E CDK2 Cyclin A CDK1 Cyclin A/B M G1 S G2 CELL DIVISION

  18. Slide 18: BLU-222 is advancing toward clinical proof-of-concept

    Slide 18: BLU-222 is advancing toward clinical proof-of-concept

    BLU-222 is advancing toward clinical proof-of-concept CCNE1, cyclin E; CDK4/6i, CDK4/6 inhibitor; ER, estrogen receptor. 18 Multiple dose cohorts* RP2D Combo with ER antagonist – ER+/HER2- breast Combo with CDK4/6i + ER antagonist – ER+/HER2- breast Monotherapy – CCNE1 tumors PHASE 2 EXPANSION (PLAN

  19. Slide 19: Anticipated clinical data milestones over the next year

    Slide 19: Anticipated clinical data milestones over the next year

    Anticipated clinical data milestones over the next year POC, proof-of-concept 19 Topline results, with additional detail presented at a medical conference at a later date Late summer 2022 2H 2022 1H 2023 Clinical data for BLU-222 Clinical data for BLU-451 Early clinical data for BLU-945+osimertinib,

  20. Slide 20: Leading Precision Medicines Drug Discovery Platform

    Slide 20: Leading Precision Medicines Drug Discovery Platform

    Leading Precision Medicines Drug Discovery Platform Diane L. Lung cancer patient Not for promotional use.

  21. Slide 21: Research platform expansion to drive innovation & expanded productivity

    Slide 21: Research platform expansion to drive innovation & expanded productivity

    Research platform expansion to drive innovation & expanded productivity 21 KINASE PLATFORM KINASE PLATFORM NEW PLATFORMS INTEGRATED PLATFORM CURRENT CAPABILITIES TARGETED PROTEIN DEGRADATION UNPARALLELED PRODUCTIVITY COMPLEMENTARY & SCALABLE NEW TARGET CLASSES LIBRARY & NEW TARGET DISCOVERY EXPANSIO

  22. Slide 22: Business development plays a key role in value creation and long-term portfolio growth

    Slide 22: Business development plays a key role in value creation and long-term portfolio growth

    Business development plays a key role in our company's value creation and long-term portfolio growth 22 Global Strategic Partnerships Access complementary expertise to maximize program value and global impact on patients Geographic Expansion Pioneering early development partnerships in China; expand

  23. Slide 23: Strong financial position with total revenues estimated for 2022 between $180 and $200 million

    Slide 23: Strong financial position with total revenues estimated for 2022 between $180 and $200 million

    Strong financial position with total revenues currently estimated for 2022 between $180 and $200 million 1. Includes stock-based compensation expense of $10.0M and $8.9M in the three months ended 3/31/22 and 3/31/21, respectively. 2. Includes stock-based compensation expense of $13.4M and $11.7M in

  24. Slide 24: Blueprint is uniquely positioned with a diversity of significant growth drivers

    Slide 24: Blueprint is uniquely positioned with a diversity of significant growth drivers

    Blueprint is uniquely positioned with a diversity of significant growth drivers Ongoing global collaboration with Roche and Genentech for the development and commercialization of GAVRETO. FDA, U.S. Food and Drug Administration; EC, European Commission; PDGFRA, platelet-derived growth factor receptor

Source: SEC EDGAR · 8-K filed Jun 9, 2022

More decks from Blueprint Medicines Corp